GlassScriptPhysician profile
Dixie D Griffin
NPI 1801015367
$8,950.49
in general payments reported to CMS, 2019-2025
36 companies · $2,508 in 2025
The $2,508 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $79.96 · 2021: $374 · 2022: $1,197 · 2023: $1,863 · 2024: $2,177 · 2025: $2,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,444 · Consulting Fee: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,444.45 |
| Consulting Fee | $104.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,722.36 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,266.05 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $976.97 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $705.73 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $693.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $557.14 | 2019-2025 | Cuvitru, Glassia, Takhzyro |
| Csl Behring | $508.83 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $314.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $311.24 | 2023-2025 | |
| Amgen INC. | $309.95 | 2022-2025 | Tezspire, Actimmune |
| Blueprint Medicines Corporation | $230.43 | 2022-2024 | Ayvakit |
| Pharming Healthcare, INC. | $203.38 | 2019-2025 | Ruconest |
| Alk-Abello, INC | $122.00 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $115.21 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $104.17 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $101.66 | 2021-2022 | |
| Genentech USA, INC. | $86.61 | 2024-2025 | Xolair |
| Incyte Corporation | $81.77 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $59.04 | 2022-2025 | Anzupgo |
| Cycle Pharmaceuticals INC | $55.83 | 2025 | Sajazir |
| Octapharma USA, INC. | $55.39 | 2022-2023 | Cutaquig |
| Galderma Laboratories, L.P. | $48.01 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $45.70 | 2022 | |
| Optinose US, INC. | $42.07 | 2019-2021 | |
| Kaleo, INC. | $29.80 | 2020 | |
| X4 Pharmaceuticals, INC. | $24.98 | 2024 | Xolremdi |
| Ionis Pharmaceuticals, INC. | $23.59 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.18 | 2025 | Ofev |
| Dermavant Sciences, INC. | $20.85 | 2024 | Vtama |
| Mirum Pharmaceuticals, INC. | $20.30 | 2025 | Livmarli |
| Biocryst US Sales Co., LLC | $18.32 | 2021 | |
| Merck Sharp & Dohme LLC | $15.85 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.82 | 2025 | Xhance |
| Sanofi Pasteur INC. | $13.97 | 2019 | |
| Shire North American Group INC | $13.91 | 2019 | |
| Neos Therapeutics, LP | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixie Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.